Protagonist Therapeutics, Inc. (PTGX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$145.72-2.07%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PTGX
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(5.8) + peer(0.2*0.0) + term(0.0) → 2.04% (capped ±15.0)
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On August 5, 2026, Protagonist Therapeutics, Inc. (the “Company”) reported its financial results for the quarter ended June 30, 2026. A copy of the press release titled “Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update” is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On May 5, 2026, Protagonist Therapeutics, Inc. reported its financial results for the quarter ended March 31, 2026. A copy of the press release titled “Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update” is furnished pursuant to
Results of Operations and Financial Condition. On February 25, 2026, Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release titled “Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update” is furnished pursuant to
Results of Operations and Financial Condition. On November 6, 2025, Protagonist Therapeutics, Inc. reported its financial results for the quarter ended September 30, 2025. A copy of the press release titled “Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update” is furnished pursuant to
Results of Operations and Financial Condition. On August 6, 2025, Protagonist Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2025. A copy of the press release titled “Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update” is furnished pursuant to
Results of Operations and Financial Condition. On May 6, 2025, Protagonist Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2025. A copy of the press release titled “Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update” is furnished pursuant to
Results of Operations and Financial Condition. On February 21, 2025, Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024. A copy of the press release titled “Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update” is furnished pursuant to
Results of Operations and Financial Condition. On November 7, 2024, Protagonist Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2024. A copy of the press release titled “Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update” is furnished pursuant to
Results of Operations and Financial Condition. On August 6, 2024, Protagonist Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2024. A copy of the press release titled “Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update” is furnished pursuant to
Results of Operations and Financial Condition. On May 7, 2024, Protagonist Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2024. A copy of the press release titled “Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update” is furnished pursuant to